Didier Colau

8.2k total citations · 1 hit paper
66 papers, 6.5k citations indexed

About

Didier Colau is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Didier Colau has authored 66 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Immunology, 28 papers in Molecular Biology and 19 papers in Oncology. Recurrent topics in Didier Colau's work include Immunotherapy and Immune Responses (31 papers), T-cell and B-cell Immunology (26 papers) and Immune Cell Function and Interaction (22 papers). Didier Colau is often cited by papers focused on Immunotherapy and Immune Responses (31 papers), T-cell and B-cell Immunology (26 papers) and Immune Cell Function and Interaction (22 papers). Didier Colau collaborates with scholars based in Belgium, France and United States. Didier Colau's co-authors include Benoı̂t J. Van den Eynde, Vincent Stroobant, Thierry Boon, Luc Pilotte, Catherine Uyttenhove, Nicolas Parmentier, Ivan Théate, Pierre G. Coulie, Laure Dumoutier and Jean‐Christophe Renauld and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Nature Medicine.

In The Last Decade

Didier Colau

65 papers receiving 6.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

2003 1.8k citations Catherine Uyttenhove, Luc Pilotte et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Didier Colau Belgium	36	3.5k	2.3k	2.1k	1.5k	546	66	6.5k
Madhav Sharma United States	20	3.6k 1.0×	1.1k 0.5×	1.4k 0.7×	2.2k 1.5×	575 1.1×	37	5.9k
Ivan Théate Belgium	23	1.8k 0.5×	1.2k 0.5×	1.4k 0.7×	1.0k 0.7×	335 0.6×	61	4.3k
Benoı̂t J. Van den Eynde Belgium	54	6.9k 1.9×	5.0k 2.2×	4.5k 2.1×	2.1k 1.4×	821 1.5×	119	11.6k
Roberto M. Lemoli Italy	48	3.1k 0.9×	2.1k 0.9×	1.8k 0.9×	359 0.2×	221 0.4×	239	7.7k
Peter Terness Germany	25	1.5k 0.4×	879 0.4×	438 0.2×	1.2k 0.8×	363 0.7×	98	3.4k
Galina V. Shurin United States	33	1.9k 0.5×	949 0.4×	1.4k 0.7×	270 0.2×	301 0.6×	68	3.7k
Constantin N. Baxevanis Greece	41	3.4k 1.0×	1.9k 0.8×	2.2k 1.0×	145 0.1×	140 0.3×	158	6.5k
David Male United Kingdom	40	1.6k 0.4×	1.7k 0.8×	1.1k 0.5×	119 0.1×	99 0.2×	101	5.6k
Anuja Ghorpade United States	41	877 0.2×	1.3k 0.6×	417 0.2×	325 0.2×	75 0.1×	85	4.8k
Bin Zhang United States	46	2.9k 0.8×	2.3k 1.0×	2.9k 1.4×	87 0.1×	159 0.3×	167	6.2k

Countries citing papers authored by Didier Colau

Since Specialization

Citations

This map shows the geographic impact of Didier Colau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Didier Colau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Didier Colau more than expected).

Fields of papers citing papers by Didier Colau

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Didier Colau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Didier Colau. The network helps show where Didier Colau may publish in the future.

Co-authorship network of co-authors of Didier Colau

This figure shows the co-authorship network connecting the top 25 collaborators of Didier Colau. A scholar is included among the top collaborators of Didier Colau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Didier Colau. Didier Colau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sorgeloos, Frédéric, Michael Peeters, Yohei Hayashi, et al.. (2022). A case of convergent evolution: Several viral and bacterial pathogens hijack RSK kinases through a common linear motif. Proceedings of the National Academy of Sciences. 119(5). 18 indexed citations

Gordón‐Alonso, Mónica, et al.. (2019). Reverse immunology: From peptide sequence to tumor-killing human T-cell clones. Methods in enzymology on CD-ROM/Methods in enzymology. 631. 159–194. 1 indexed citations

Lopes, Alessandra, Kévin Vanvarenberg, Špela Kos, et al.. (2018). Combination of immune checkpoint blockade with DNA cancer vaccine induces potent antitumor immunity against P815 mastocytoma. Scientific Reports. 8(1). 15732–15732. 25 indexed citations

Lopez, Marc, Danièle Godelaine, Javier Carrasco, et al.. (2016). Identification of a naturally processed HLA-A*02:01-restricted CTL epitope from the human tumor-associated antigen Nectin-4. Cancer Immunology Immunotherapy. 65(10). 1177–1188. 9 indexed citations

Rieux, Anne des, Bernard Učakar, Didier Colau, et al.. (2010). 3D systems delivering VEGF to promote angiogenesis for tissue engineering. Journal of Controlled Release. 150(3). 272–278. 109 indexed citations

Parmentier, Nicolas, Vincent Stroobant, Didier Colau, et al.. (2010). Production of an antigenic peptide by insulin-degrading enzyme. Nature Immunology. 11(5). 449–454. 53 indexed citations

Dolušić, Eduard, Pierre Larrieu, Sébastien Blanc, et al.. (2010). Indol-2-yl ethanones as novel indoleamine 2,3-dioxygenase (IDO) inhibitors. Bioorganic & Medicinal Chemistry. 19(4). 1550–1561. 34 indexed citations

François, Violaine, Nicolina Renkvist, Julie Stockis, et al.. (2009). The CD4+ T-Cell Response of Melanoma Patients to a MAGE-A3 Peptide Vaccine Involves Potential Regulatory T Cells. Cancer Research. 69(10). 4335–4345. 77 indexed citations

Stockis, Julie, Didier Colau, Pierre G. Coulie, & Sophie Lucas. (2009). Membrane protein GARP is a receptor for latent TGF‐β on the surface of activated human Treg. European Journal of Immunology. 39(12). 3315–3322. 206 indexed citations

10.

Neto, Mário de Oliveira, José Ribamar Ferreira-Júnior, Didier Colau, et al.. (2007). Interleukin-22 Forms Dimers that are Recognized by Two Interleukin-22R1 Receptor Chains. Biophysical Journal. 94(5). 1754–1765. 45 indexed citations

11.

Pietra, Gabriella, Paola Vacca, Michela Falco, et al.. (2005). Identification of effector-memory CMV-specific T lymphocytes that kill CMV-infected target cells in an HLA-E-restricted fashion. European Journal of Immunology. 35(11). 3240–3247. 69 indexed citations

12.

Colau, Didier, et al.. (2005). A new MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA–A24 carcinoma cells. Cancer Immunology Immunotherapy. 55(7). 867–872. 10 indexed citations

13.

Karanikas, Vaios, Christophe Lurquin, Didier Colau, et al.. (2003). Monoclonal Anti-MAGE-3 CTL Responses in Melanoma Patients Displaying Tumor Regression after Vaccination with a Recombinant Canarypox Virus. The Journal of Immunology. 171(9). 4898–4904. 88 indexed citations

14.

Uyttenhove, Catherine, Luc Pilotte, Ivan Théate, et al.. (2003). Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nature Medicine. 9(10). 1269–1274. 1807 indexed citations breakdown →

15.

Kobayashi, Tatsuya, Christophe Lonchay, Didier Colau, et al.. (2003). New MAGE‐4 antigenic peptide recognized by cytolytic T lymphocytes on HLA‐A1 tumor cells. Tissue Antigens. 62(5). 426–432. 13 indexed citations

16.

Bilsborough, Janine, Catherine Uyttenhove, Didier Colau, et al.. (2002). TNF-Mediated Toxicity After Massive Induction of Specific CD8+ T Cells Following Immunization of Mice with a Tumor-Specific Peptide. The Journal of Immunology. 169(6). 3053–3060. 17 indexed citations

17.

Denis, Olivier, Vincent Stroobant, Didier Colau, Sushila D’Souza, & Kris Huygen. (2002). Culture filtrate specific H-2b restricted CD8+ T cells activated in vivo by Mycobacterium tuberculosis or bovis BCG recognize a restricted number of immunodominant peptides. Immunology Letters. 81(2). 115–124. 4 indexed citations

18.

Nagem, Ronaldo Alves Pinto, et al.. (2002). Crystallization and synchrotron X-ray diffraction studies of human interleukin-22. Acta Crystallographica Section D Biological Crystallography. 58(3). 529–530. 7 indexed citations

19.

Baurain, Jean‐François, Didier Colau, Nicolas van Baren, et al.. (2000). High Frequency of Autologous Anti-Melanoma CTL Directed Against an Antigen Generated by a Point Mutation in a New Helicase Gene. The Journal of Immunology. 164(11). 6057–6066. 83 indexed citations

20.

Colau, Didier, et al.. (1986). Gene tagging in plants by a T-DNA insertion mutagen that generates APH(3′)II-plant gene fusions. Molecular and General Genetics MGG. 204(3). 512–518. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact